Peptides occupy a unique position in biochemical research — they are structurally simpler than proteins, more complex than small molecules, and capable of highly selective biological activity that neither category fully replicates. This primer covers the foundational concepts needed to contextualize peptide research: structure, synthesis, delivery, classification, and the distinction between research-use and clinical compounds.
Structure: What Makes a Peptide
A peptide is a chain of amino acids linked by peptide bonds — the covalent bonds formed between the carboxyl group of one amino acid and the amino group of the next, with loss of a water molecule. By convention, chains of fewer than 50 amino acids are typically classified as peptides, while longer chains are proteins, though this boundary is not strict.
The biological activity of a peptide is determined by its amino acid sequence (primary structure), which governs how it folds, what receptors or enzymes it interacts with, and how it is recognized and degraded by proteases. Even single amino acid substitutions can dramatically alter activity, selectivity, and stability — a principle that underlies the design of most synthetic research peptides.
Synthesis: How Research Peptides Are Made
Modern research peptides are predominantly produced by solid-phase peptide synthesis (SPPS), a technique pioneered by R. Bruce Merrifield, who was awarded the Nobel Prize in Chemistry in 1984 for this work. SPPS allows sequential assembly of amino acids on a solid resin support, with each amino acid added and protected/deprotected in controlled steps.
The resulting crude peptide is purified by high-performance liquid chromatography (HPLC) and its identity confirmed by mass spectrometry. Purity specifications for research-grade peptides typically require ≥98% HPLC purity, with mass accuracy confirmed to within 1 Da. Certificate of Analysis (COA) documents from accredited third-party laboratories serve as the standard verification method.
Stability and Delivery Challenges
Peptides face significant stability challenges that distinguish them from small-molecule compounds. Proteases in biological fluids rapidly cleave peptide bonds — the half-life of many unmodified peptides in plasma is measured in minutes. This degradation limits oral bioavailability and constrains delivery options.
Research peptides are typically lyophilized (freeze-dried) for storage, which removes water and dramatically slows degradation. Upon reconstitution in sterile or bacteriostatic water, they are administered parenterally or intranasally in research settings. Chemical modifications such as N-terminal acetylation, C-terminal amidation, or cyclization are often used to increase resistance to exopeptidases.
Classification by Function
Research peptides can be broadly classified by their primary biological activity. Regenerative peptides — including BPC-157 and TB-500 — are studied for their effects on tissue repair, angiogenesis, and wound healing. Nootropic peptides — including SEMAX and SELANK — target CNS function, neurotrophic factor expression, and neurotransmitter modulation.
Other categories include antimicrobial peptides (AMPs), which disrupt bacterial membranes; peptide hormones and analogs, such as GLP-1 agonists studied in metabolic research; and structural peptides like collagen-related sequences studied in dermatological contexts. Each category has distinct target classes, delivery requirements, and research applications.
Research Use vs. Clinical Use
The designation 'for research use only' (RUO) has a specific regulatory meaning. RUO compounds are not approved for human therapeutic use and have not undergone the clinical trial process required for pharmaceutical approval. They are intended for laboratory and preclinical research.
The existence of preclinical research data — even robust, replicated data — does not constitute regulatory approval or clinical evidence of safety and efficacy in humans. Researchers working with peptides should be familiar with applicable institutional, national, and international regulations governing their use.
Research Disclaimer: This article is intended for educational and research purposes only. All findings referenced are from published preclinical, in vitro, or animal studies. Results observed in laboratory models may not translate to human outcomes. Nothing in this article constitutes medical advice. Genfinite products are sold strictly for scientific research use only and are not intended for human consumption.
References
- 1.Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemical Society. 1963. DOI: 10.1021/ja00897a025
- 2.Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015. DOI: 10.1016/j.drudis.2014.10.003 PubMed: 25308539
- 3.Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discovery Today. 2010. DOI: 10.1016/j.drudis.2009.10.009 PubMed: 19879957